BioPharmSignal logoBioPharmSignal

Biotech News

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

Oculis (OCS)OculisCompany update

Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron Tansy, M.D., appointed as Vice President, Development Franchise Head,

Related news

OCSOculis2026-10-22 06:00 EST

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

OCSOculis2026-10-20 06:00 EST

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

TARSTarsus Pharmaceuticals2026-10-28 12:30 EST

Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial Officer

OTLKOutlook2026-08-27 20:05 EST

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

OKYOOKYO Pharma2026-07-28 11:00 EST

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

EYPTEyePoint Pharmaceuticals2026-07-13 11:00 EST

EyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science Officer

OCULOcular Therapeutix2026-10-29 11:00 EST

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

OTLKOutlook2026-10-09 12:30 EST

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

OCULOcular Therapeutix2026-10-01 11:00 EST

Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences

PRQRProQR Therapeutics2026-09-23 12:00 EST

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

View all latest news

Oculis

Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...

Recent company news

OCSOculis2026-11-03 21:05 EST

Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts

OCSOculis2026-11-02 07:00 EST

Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

OCSOculis2026-10-29 09:39 EST

Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

OCSOculis2026-10-22 06:00 EST

Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

OCSOculis2026-10-20 06:00 EST

Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

Stock data

Close
6.83 USD
Market cap
742.17M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States